Form 8-K - Current report:
SEC Accession No. 0001649094-25-000027
Filing Date
2025-02-25
Accepted
2025-02-25 16:04:29
Documents
15
Period of Report
2025-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcvx-20250225.htm   iXBRL 8-K 27382
2 EX-99.1 pcvx-20250225xexx991.htm EX-99.1 89622
6 image_0a.jpg GRAPHIC 12018
  Complete submission text file 0001649094-25-000027.txt   274677

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcvx-20250225.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcvx-20250225_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcvx-20250225_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-20250225_htm.xml XML 3005
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39323 | Film No.: 25662952
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)